Literature DB >> 2561919

Liver transplantation for malignant tumours.

B Ringe, R Pichlmayr.   

Abstract

Despite considerable overall progress in human liver transplantation the results obtained in patients with malignant tumours have not improved significantly over the past years. One of the crucial questions in the ongoing controversial discussion remains the identification of tumour patients with the most favourable prognosis. In a consecutive series of 114 patients who received hepatic transplants for various malignant tumours of the liver and biliary tract, at least some factors could be shown to play a prognostic role. Regarding the histological type of tumour, fibrolamellar carcinoma, epitheloid haemangioendothelioma, and endocrine hepatic metastases seem to have a better long-term survival, whereas cholangiocellular carcinoma and other liver metastases had the worst outcome. In patients with primary liver or proximal bile duct cancer there was a significant influence of the pathological tumour stage at the time of transplantation: significant palliation or cure was almost essentially restricted to patients with early tumour stages as compared with advanced primary tumours and extrahepatic spread where early tumour recurrence developed in all recipients. Thus, the present concept for the treatment of malignant hepatobiliary tumours should include partial as well as total hepatectomy with subsequent liver replacement. In cases of non-resectable lesions or intrahepatic tumour recurrence following previous resection, liver transplantation offers the only chance for long-term survival.

Entities:  

Mesh:

Year:  1989        PMID: 2561919     DOI: 10.1016/0950-3528(89)90032-8

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  4 in total

1.  Metachronous pulmonary and adrenal metastases after liver transplantation for hepatocarcinoma.

Authors:  Shan-Wen Chen; Shuo Wang; Bo Wang; Wei-Dong Li; Sheng Yan; Li-Ping Xie
Journal:  World J Surg Oncol       Date:  2011-11-28       Impact factor: 2.754

2.  Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.

Authors:  M Monden; M Sakon; M Gotoh; T Kanai; K Umeshita; K S Wang; M Sakurai; C Kuroda; J Okamura; T Mori
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Liver transplantation for hepatocellular carcinoma: clinical results and future aspects.

Authors:  R Pichlmayr; A Weimann; G Steinhoff; B Ringe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  A case of a resectable single hepatic epithelioid hemangioendothelioma with characteristic imaging by ADC map.

Authors:  Hiroshi Okano; Hideki Nakajima; Tomomasa Tochio; Daisuke Suga; Hiroaki Kumazawa; Yoshiaki Isono; Hiroki Tanaka; Shimpei Matsusaki; Tomohiro Sase; Tomonori Saito; Katsumi Mukai; Akira Nishimura; Nobuyoshi Matsushima; Youichirou Baba; Tetsuya Murata; Takashi Hamada; Hiroki Taoka
Journal:  Clin J Gastroenterol       Date:  2015-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.